2023-03-15 16:11:09 ET
- MaxCyte press release ( NASDAQ: MXCT ): Q4 GAAP EPS of -$0.05 beats by $0.02 .
- Revenue of $10.88M (+7.2% Y/Y) misses by $2.25M .
- Initial 2023 guidance for total revenue growth of 21% to 26% over 2022, including core revenue growth of 20% to 25% over 2022, and Strategic Platform License program-related revenue of approximately $6 million.
- Total cash, cash equivalents and short-term investments were $227.3 million as of December 31, 2022.
For further details see:
MaxCyte GAAP EPS of -$0.05 beats by $0.02, revenue of $10.88M misses by $2.25M